No data to show
XNAS
IOBT
Market cap56mUSD
Apr 10, Last price
0.86USD
1D
-2.30%
1Q
-1.52%
IPO
-93.48%
Name
IO Biotech Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
0k
Net income
-86m
L+20.47%
CFO
-72m
L+20.10%
Profile
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 2 clinical trial to treat melanoma, as well as in phase 1 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||
Revenues | |||||
Cost of revenue | 92,199 | 71,964 | |||
Unusual Expense (Income) | |||||
NOPBT | (92,199) | (71,964) | |||
NOPBT Margin | |||||
Operating Taxes | 852 | 1,273 | |||
Tax Rate | |||||
NOPAT | (93,051) | (73,237) | |||
Net income | (86,083) 20.47% | (71,458) 5.27% | |||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | 75,058 | ||||
BB yield | -91.70% | ||||
| Debt | |||||
Debt current | 1,310 | 515 | |||
Long-term debt | 4,333 | 5,065 | |||
Deferred revenue | |||||
Other long-term liabilities | |||||
Net debt | (137,550) | (137,278) | |||
| Cash flow | |||||
Cash from operating activities | (71,737) | (59,729) | |||
CAPEX | (323) | (690) | |||
Cash from investing activities | (323) | (690) | |||
Cash from financing activities | 71,860 | ||||
FCF | (92,923) | (76,316) | |||
| Balance | |||||
Cash | 143,193 | 142,590 | |||
Long term investments | 268 | ||||
Excess cash | 143,193 | 142,858 | |||
Stockholders' equity | (273,425) | (187,851) | |||
Invested Capital | 409,736 | 329,495 | |||
ROIC | |||||
ROCE | |||||
| EV | |||||
Common stock shares outstanding | 43,540 | 28,815 | |||
Price | 1.88 -18.26% | 2.30 -64.06% | |||
Market cap | 81,855 23.51% | 66,275 -64.06% | |||
EV | (55,695) | (71,003) | |||
EBITDA | (91,443) | (71,424) | |||
EV/EBITDA | 0.61 | 0.99 | |||
Interest | 302 | ||||
Interest/NOPBT | |||||